These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 27441547)

  • 41. Eltoprazine prevents levodopa-induced dyskinesias by reducing striatal glutamate and direct pathway activity.
    Paolone G; Brugnoli A; Arcuri L; Mercatelli D; Morari M
    Mov Disord; 2015 Nov; 30(13):1728-38. PubMed ID: 26207892
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Neurokinin B/NK3 receptors exert feedback inhibition on L-DOPA actions in the 6-OHDA lesion rat model of Parkinson's disease.
    Zhang X; Andren PE; Chergui K; Svenningsson P
    Neuropharmacology; 2008 Jun; 54(7):1143-52. PubMed ID: 18423776
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The CB1 cannabinoid receptor agonist reduces L-DOPA-induced motor fluctuation and ERK1/2 phosphorylation in 6-OHDA-lesioned rats.
    Song L; Yang X; Ma Y; Wu N; Liu Z
    Drug Des Devel Ther; 2014; 8():2173-9. PubMed ID: 25395834
    [TBL] [Abstract][Full Text] [Related]  

  • 44. L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia.
    Lindgren HS; Andersson DR; Lagerkvist S; Nissbrandt H; Cenci MA
    J Neurochem; 2010 Mar; 112(6):1465-76. PubMed ID: 20050978
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pentobarbital inhibits L-DOPA-induced dopamine increases in the rat striatum: An in vivo microdialysis study.
    Adachi YU; Yamada S; Satomoto M; Watanabe K; Higuchi H; Kazama T; Doi M; Sato S
    Brain Res Bull; 2006 May; 69(5):593-6. PubMed ID: 16647588
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Simultaneous decoupled detection of dopamine and oxygen using pyrolyzed carbon microarrays and fast-scan cyclic voltammetry.
    Zachek MK; Takmakov P; Moody B; Wightman RM; McCarty GS
    Anal Chem; 2009 Aug; 81(15):6258-65. PubMed ID: 19552423
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The medical treatment of Parkinson disease from James Parkinson to George Cotzias.
    Fahn S
    Mov Disord; 2015 Jan; 30(1):4-18. PubMed ID: 25491387
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Quantitative Comparison of Enzyme Immobilization Strategies for Glucose Biosensing in Real-Time Using Fast-Scan Cyclic Voltammetry Coupled with Carbon-Fiber Microelectrodes.
    Smith SK; Lugo-Morales LZ; Tang C; Gosrani SP; Lee CA; Roberts JG; Morton SW; McCarty GS; Khan SA; Sombers LA
    Chemphyschem; 2018 May; 19(10):1197-1204. PubMed ID: 29316144
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Levodopa/benserazide microsphere (LBM) prevents L-dopa induced dyskinesia by inactivation of the DR1/PKA/P-tau pathway in 6-OHDA-lesioned Parkinson's rats.
    Xie CL; Wang WW; Zhang SF; Yuan ML; Che JY; Gan J; Song L; Yuan WE; Liu ZG
    Sci Rep; 2014 Dec; 4():7506. PubMed ID: 25511986
    [TBL] [Abstract][Full Text] [Related]  

  • 50. C-FSCV: Compressive Fast-Scan Cyclic Voltammetry for Brain Dopamine Recording.
    Zamani H; Bahrami HR; Chalwadi P; Garris PA; Mohseni P
    IEEE Trans Neural Syst Rehabil Eng; 2018 Jan; 26(1):51-59. PubMed ID: 29324402
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease.
    Pinna A; Ko WK; Costa G; Tronci E; Fidalgo C; Simola N; Li Q; Tabrizi MA; Bezard E; Carta M; Morelli M
    Mov Disord; 2016 Apr; 31(4):501-11. PubMed ID: 26871939
    [TBL] [Abstract][Full Text] [Related]  

  • 52. 5-Hydroxy-tryptophan for the treatment of L-DOPA-induced dyskinesia in the rat Parkinson's disease model.
    Tronci E; Lisci C; Stancampiano R; Fidalgo C; Collu M; Devoto P; Carta M
    Neurobiol Dis; 2013 Dec; 60():108-14. PubMed ID: 24004632
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of chronic treatment with angiotensin type 1 receptor antagonists on striatal dopamine levels in normal rats and in a rat model of Parkinson's disease treated with L-DOPA.
    Dominguez-Meijide A; Villar-Cheda B; Garrido-Gil P; Sierrra-Paredes G; Guerra MJ; Labandeira-Garcia JL
    Neuropharmacology; 2014 Jan; 76 Pt A():156-68. PubMed ID: 23973568
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Chronic salsolinol administration prevents the behavioral and neurochemical effects of L-DOPA in rats.
    Wąsik A; Romańska I; Michaluk J; Antkiewicz-Michaluk L
    Neurotox Res; 2015 May; 27(4):399-410. PubMed ID: 25711629
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Monoamine transporter contributions to l-DOPA effects in hemi-parkinsonian rats.
    Conti MM; Meadows SM; Melikhov-Sosin M; Lindenbach D; Hallmark J; Werner DF; Bishop C
    Neuropharmacology; 2016 Nov; 110(Pt A):125-134. PubMed ID: 27452719
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Coadministration of β-asarone and levodopa increases dopamine in rat brain by accelerating transformation of levodopa: a different mechanism from Madopar.
    Huang L; Deng M; Zhang S; Fang Y; Li L
    Clin Exp Pharmacol Physiol; 2014 Sep; 41(9):685-90. PubMed ID: 24910244
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The neurochemistry of Parkinson's disease: effect of L-dopa therapy.
    Lloyd KG; Davidson L; Hornykiewicz O
    J Pharmacol Exp Ther; 1975 Dec; 195(3):453-64. PubMed ID: 489
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Unpredictable rotational responses to L-dopa in the rat model of Parkinson's disease: the role of L-dopa pharmacokinetics and striatal dopamine depletion.
    Kääriäinen TM; Käenmäki M; Forsberg MM; Oinas N; Tammimäki A; Männistö PT
    Basic Clin Pharmacol Toxicol; 2012 Feb; 110(2):162-70. PubMed ID: 21848668
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Nafion-CNT coated carbon-fiber microelectrodes for enhanced detection of adenosine.
    Ross AE; Venton BJ
    Analyst; 2012 Jul; 137(13):3045-51. PubMed ID: 22606688
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Serotonergic nerve fibers in L-DOPA-derived dopamine release and dyskinesia.
    Nevalainen N; Af Bjerkén S; Gerhardt GA; Strömberg I
    Neuroscience; 2014 Feb; 260():73-86. PubMed ID: 24361918
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.